Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

02 mars 2016 19h48 HE | Source: Alimera Sciences, Inc.

Alimera Sciences Reports Record Fourth Quarter and Full Year 2015 Financial Results

Annual revenue increased 167% for 2015 compared to 2014Record fourth quarter 2015 revenue increased 241% over fourth quarter 2014Company to host conference call on March 3, 2016 at 10:00 AM ET ...
29 févr. 2016 07h30 HE | Source: Alimera Sciences, Inc.

Alimera Sciences to Present at 36th Annual Cowen Healthcare Conference

ATLANTA, Feb. 29, 2016 (GLOBE NEWSWIRE) -- Alimera Sciences (NASDAQ:ALIM), a leader in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced...
18 févr. 2016 07h30 HE | Source: Alimera Sciences, Inc.

Alimera Sciences to Report Fourth Quarter 2015 Financial Results on March 2, 2016

ALPHARETTA, Ga., Feb. 18, 2016 (GLOBE NEWSWIRE) -- Alimera Sciences (NASDAQ:ALIM), a leader in research, development and commercialization of prescription ophthalmic pharmaceuticals, today...
09 août 2012 16h01 HE | Source: Alimera Sciences, Inc.

Alimera Sciences Reports Second Quarter 2012 Financial Results

Company Expects to Begin Generating Revenue in the First Quarter of 2013 Alimera Will Host a Conference Call at 4:30 P.M. ET Today ATLANTA, Aug. 9, 2012 (GLOBE NEWSWIRE) -- Alimera Sciences,...
30 juil. 2012 12h15 HE | Source: Alimera Sciences, Inc.

Alimera Sciences to Release Second Quarter Fiscal Year 2012 Financial Results

ATLANTA, July 30, 2012 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq:ALIM) ("Alimera"), a biopharmaceutical company that specializes in the research, development and commercialization of...
18 juil. 2012 09h56 HE | Source: Alimera Sciences, Inc.

Alimera Sciences' ILUVIEN(R) Receives Marketing Authorization in France for the Treatment of Chronic Diabetic Macular Edema

ATLANTA, July 18, 2012 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc., (Nasdaq:ALIM) (Alimera), a biopharmaceutical company that specializes in the research, development and commercialization of...
18 juil. 2012 07h00 HE | Source: Alimera Sciences, Inc.

Alimera Sciences Agrees to Sell $40 Million of Convertible Preferred Stock

Company Hosting Analyst Day Today in NYC to Discuss Update on ILUVIEN Market Opportunity in Europe; Webcast Available for Replay Dr. Garheng Kong to join Board of Directors upon...
26 juin 2012 11h30 HE | Source: Alimera Sciences, Inc.

Alimera Sciences to Webcast 2012 Analyst Day

ATLANTA, June 26, 2012 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc., (Nasdaq:ALIM) (Alimera), a biopharmaceutical company that specializes in the research, development and commercialization of...
05 juin 2012 08h00 HE | Source: Alimera Sciences, Inc.

Alimera Sciences' ILUVIEN(R) Receives Marketing Authorization in Portugal for the Treatment of Chronic Diabetic Macular Edema

ATLANTA, June 5, 2012 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc., (Nasdaq:ALIM) (Alimera), a biopharmaceutical company that specializes in the research, development and commercialization of...
11 mai 2012 06h45 HE | Source: Alimera Sciences, Inc.

Alimera Sciences Reports First Quarter 2012 Financial Results

Cash and Cash Equivalents at March 31, 2012 Totaled $27.6 Million Alimera Will Host a Conference Call at 8:30 A.M. ET Today ATLANTA, May 11, 2012 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc.,...

Page précédente